NasdaqGM - Delayed Quote • USD
Aerovate Therapeutics, Inc. (AVTE)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 4:20 PM EDT
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Timothy P. Noyes M.B.A. | CEO & Director | 936.9k | -- | 1962 |
Mr. George A. Eldridge | CFO & Treasurer | 658.6k | -- | 1963 |
Mr. Timothy J. Pigot | Chief Commercial Officer | 584.6k | -- | 1971 |
Dr. Benjamin T. Dake Ph.D. | Founder, President, COO & Secretary | 435.5k | -- | 1976 |
Dr. Marinus Verwijs Ph.D. | Chief Technical Officer | 439.88k | -- | 1976 |
Dr. Ralph W. Niven M.B.A., M.R, Ph.D., Pharm.S | Chief Scientific Officer | 372.33k | -- | 1960 |
Mr. Hunter Gillies M.D. | Chief Medical Officer | 512.74k | -- | 1966 |
Ms. Donna Dea | Head of Regulatory Affairs | -- | -- | -- |
Ms. Susan Fischer | Executive Vice President of Development Operations | -- | -- | -- |
Mr. Stephen K. Yu | Senior Vice President of Quality | -- | -- | -- |
Aerovate Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 51
Description
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Corporate Governance
Aerovate Therapeutics, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 8. The pillar scores are Audit: 8; Board: 8; Shareholder Rights: 8; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
- Mar 27, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 25, 202410-K: Periodic Financial ReportsSee Full Filing
- Jan 08, 2024S-8: Offering RegistrationsSee Full Filing
- Nov 20, 20238-K: Corporate Changes & Voting MattersSee Full Filing
- Nov 13, 202310-Q: Periodic Financial ReportsSee Full Filing
Upcoming Events
May 13, 2024 - May 17, 2024
Aerovate Therapeutics, Inc. Earnings Call
Related Tickers
TYRA Tyra Biosciences, Inc.
15.67
+3.71%
KROS Keros Therapeutics, Inc.
57.86
+6.77%
NAMS NewAmsterdam Pharma Company N.V.
21.99
+2.57%
ATXS Astria Therapeutics, Inc.
9.00
-1.85%
EWTX Edgewise Therapeutics, Inc.
16.17
+1.44%
DNTH Dianthus Therapeutics, Inc.
21.50
+2.43%
FULC Fulcrum Therapeutics, Inc.
7.14
+0.14%
AVBP ArriVent BioPharma, Inc.
15.44
-0.64%
LXEO Lexeo Therapeutics, Inc.
12.50
+2.80%
CELC Celcuity Inc.
15.92
+0.95%